Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis

Imran H. Khan, Resmi Ravindran, JoAnn Yee, Melanie Ziman, David Lewinsohn, Marila L. Gennaro, JoAnne L. Flynn, Celia W. Goulding, Kathryn DeRiemer, Nickolas W. Lerche, Paul A. Luciw

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Tuberculosis (TB) is a serious global disease. The fatality rate attributed to TB is among the highest of infectious diseases, with approximately 2 million deaths occurring per year worldwide. Identification of individuals infected with Mycobacterium tuberculosis and screening of their immediate contacts is crucial for controlling the spread of TB. Current methods for detection of M. tuberculosis infection are not efficient, in particular, for testing large numbers of samples. We report a novel and efficient multiplex microbead immunoassay (MMIA), based on Luminex technology, for profiling antibodies to M. tuberculosis. Microbead sets identifiable by unique fluorescence were individually coated with each of several M. tuberculosis antigens and tested in multiplex format for antibody detection in the experimental nonhuman primate model of TB. Certain M. tuberculosis antigens, e.g., ESAT-6, CFP-10, and HspX, were included to enhance the specificity of the MMIA, because these antigens are absent in nontuberculous mycobacteria and the vaccine strain Mycobacterium bovis bacillus Calmette-Guérin. The MMIA enabled simultaneous detection of multiple M. tuberculosis plasma antibodies in several cohorts of macaques representing different stages of infection and/or disease. Antibody profiles were defined in early and latent/chronic infection. These proof-of-concept findings demonstrate the potential clinical use of the MMIA. In addition, the MMIA serodetection system has a potential for mining M. tuberculosis open reading frames (about 4,000) to discover novel target proteins for the development of more-comprehensive TB serodiagnostic tests.

Original languageEnglish (US)
Pages (from-to)433-438
Number of pages6
JournalClinical and Vaccine Immunology
Volume15
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Serologic Tests
Microspheres
Mycobacterium tuberculosis
Suspensions
Immunoassay
Tuberculosis
Antibodies
Antigens
Bacilli
Nontuberculous Mycobacteria
Screening
Mycobacterium Infections
Vaccines
Fluorescence
Macaca
Mycobacterium bovis
Infection
Plasmas
Bacillus
Primates

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)
  • Medicine(all)

Cite this

Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. / Khan, Imran H.; Ravindran, Resmi; Yee, JoAnn; Ziman, Melanie; Lewinsohn, David; Gennaro, Marila L.; Flynn, JoAnne L.; Goulding, Celia W.; DeRiemer, Kathryn; Lerche, Nickolas W.; Luciw, Paul A.

In: Clinical and Vaccine Immunology, Vol. 15, No. 3, 03.2008, p. 433-438.

Research output: Contribution to journalArticle

Khan, IH, Ravindran, R, Yee, J, Ziman, M, Lewinsohn, D, Gennaro, ML, Flynn, JL, Goulding, CW, DeRiemer, K, Lerche, NW & Luciw, PA 2008, 'Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis', Clinical and Vaccine Immunology, vol. 15, no. 3, pp. 433-438. https://doi.org/10.1128/CVI.00354-07
Khan, Imran H. ; Ravindran, Resmi ; Yee, JoAnn ; Ziman, Melanie ; Lewinsohn, David ; Gennaro, Marila L. ; Flynn, JoAnne L. ; Goulding, Celia W. ; DeRiemer, Kathryn ; Lerche, Nickolas W. ; Luciw, Paul A. / Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. In: Clinical and Vaccine Immunology. 2008 ; Vol. 15, No. 3. pp. 433-438.
@article{3b0328598fde43b891a7943405f63394,
title = "Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis",
abstract = "Tuberculosis (TB) is a serious global disease. The fatality rate attributed to TB is among the highest of infectious diseases, with approximately 2 million deaths occurring per year worldwide. Identification of individuals infected with Mycobacterium tuberculosis and screening of their immediate contacts is crucial for controlling the spread of TB. Current methods for detection of M. tuberculosis infection are not efficient, in particular, for testing large numbers of samples. We report a novel and efficient multiplex microbead immunoassay (MMIA), based on Luminex technology, for profiling antibodies to M. tuberculosis. Microbead sets identifiable by unique fluorescence were individually coated with each of several M. tuberculosis antigens and tested in multiplex format for antibody detection in the experimental nonhuman primate model of TB. Certain M. tuberculosis antigens, e.g., ESAT-6, CFP-10, and HspX, were included to enhance the specificity of the MMIA, because these antigens are absent in nontuberculous mycobacteria and the vaccine strain Mycobacterium bovis bacillus Calmette-Gu{\'e}rin. The MMIA enabled simultaneous detection of multiple M. tuberculosis plasma antibodies in several cohorts of macaques representing different stages of infection and/or disease. Antibody profiles were defined in early and latent/chronic infection. These proof-of-concept findings demonstrate the potential clinical use of the MMIA. In addition, the MMIA serodetection system has a potential for mining M. tuberculosis open reading frames (about 4,000) to discover novel target proteins for the development of more-comprehensive TB serodiagnostic tests.",
author = "Khan, {Imran H.} and Resmi Ravindran and JoAnn Yee and Melanie Ziman and David Lewinsohn and Gennaro, {Marila L.} and Flynn, {JoAnne L.} and Goulding, {Celia W.} and Kathryn DeRiemer and Lerche, {Nickolas W.} and Luciw, {Paul A.}",
year = "2008",
month = "3",
doi = "10.1128/CVI.00354-07",
language = "English (US)",
volume = "15",
pages = "433--438",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "3",

}

TY - JOUR

T1 - Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis

AU - Khan, Imran H.

AU - Ravindran, Resmi

AU - Yee, JoAnn

AU - Ziman, Melanie

AU - Lewinsohn, David

AU - Gennaro, Marila L.

AU - Flynn, JoAnne L.

AU - Goulding, Celia W.

AU - DeRiemer, Kathryn

AU - Lerche, Nickolas W.

AU - Luciw, Paul A.

PY - 2008/3

Y1 - 2008/3

N2 - Tuberculosis (TB) is a serious global disease. The fatality rate attributed to TB is among the highest of infectious diseases, with approximately 2 million deaths occurring per year worldwide. Identification of individuals infected with Mycobacterium tuberculosis and screening of their immediate contacts is crucial for controlling the spread of TB. Current methods for detection of M. tuberculosis infection are not efficient, in particular, for testing large numbers of samples. We report a novel and efficient multiplex microbead immunoassay (MMIA), based on Luminex technology, for profiling antibodies to M. tuberculosis. Microbead sets identifiable by unique fluorescence were individually coated with each of several M. tuberculosis antigens and tested in multiplex format for antibody detection in the experimental nonhuman primate model of TB. Certain M. tuberculosis antigens, e.g., ESAT-6, CFP-10, and HspX, were included to enhance the specificity of the MMIA, because these antigens are absent in nontuberculous mycobacteria and the vaccine strain Mycobacterium bovis bacillus Calmette-Guérin. The MMIA enabled simultaneous detection of multiple M. tuberculosis plasma antibodies in several cohorts of macaques representing different stages of infection and/or disease. Antibody profiles were defined in early and latent/chronic infection. These proof-of-concept findings demonstrate the potential clinical use of the MMIA. In addition, the MMIA serodetection system has a potential for mining M. tuberculosis open reading frames (about 4,000) to discover novel target proteins for the development of more-comprehensive TB serodiagnostic tests.

AB - Tuberculosis (TB) is a serious global disease. The fatality rate attributed to TB is among the highest of infectious diseases, with approximately 2 million deaths occurring per year worldwide. Identification of individuals infected with Mycobacterium tuberculosis and screening of their immediate contacts is crucial for controlling the spread of TB. Current methods for detection of M. tuberculosis infection are not efficient, in particular, for testing large numbers of samples. We report a novel and efficient multiplex microbead immunoassay (MMIA), based on Luminex technology, for profiling antibodies to M. tuberculosis. Microbead sets identifiable by unique fluorescence were individually coated with each of several M. tuberculosis antigens and tested in multiplex format for antibody detection in the experimental nonhuman primate model of TB. Certain M. tuberculosis antigens, e.g., ESAT-6, CFP-10, and HspX, were included to enhance the specificity of the MMIA, because these antigens are absent in nontuberculous mycobacteria and the vaccine strain Mycobacterium bovis bacillus Calmette-Guérin. The MMIA enabled simultaneous detection of multiple M. tuberculosis plasma antibodies in several cohorts of macaques representing different stages of infection and/or disease. Antibody profiles were defined in early and latent/chronic infection. These proof-of-concept findings demonstrate the potential clinical use of the MMIA. In addition, the MMIA serodetection system has a potential for mining M. tuberculosis open reading frames (about 4,000) to discover novel target proteins for the development of more-comprehensive TB serodiagnostic tests.

UR - http://www.scopus.com/inward/record.url?scp=42049096819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42049096819&partnerID=8YFLogxK

U2 - 10.1128/CVI.00354-07

DO - 10.1128/CVI.00354-07

M3 - Article

C2 - 18077619

AN - SCOPUS:42049096819

VL - 15

SP - 433

EP - 438

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 3

ER -